Agios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018

CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. AGIO, a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, August 2, 2018 at 8:00 a.m. ET to report its second quarter financial results and discuss recent clinical development and corporate activities.

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 1497883. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.

About Agios

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.

Contacts

Agios Investors Contact:

Renee Leck, 617-649-8299

Senior Manager, Investor Relations

Renee.Leck@agios.com

Agios Media Contact:

Holly Manning, 617-844-6630

Associate Director, Corporate Communications

Holly.Manning@agios.com

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!